HCPCS Level IImedical_servicesActive
M1412
Met nsclc w/ egfr alk oth ab
BETOS: Z2
Effective: 2025-01-01
Description
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
Medicare Fee Schedule
2026 Medicare Physician Fee Schedule national payment rates
$0.00
Non-Facility Price
$0.00
Facility Price
0.00
Work RVU
0.00
Total RVU (Non-Fac)